135 related articles for article (PubMed ID: 9043731)
1. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
Diemunsch P; Leeser J; Feiss P; D'Hollander A; Bradburn BG; Paxton D; Whitmore J; Panouillot P; Navé S; Brown RA; Hahne WF
Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
3. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
Diemunsch P; D'Hollander A; Paxton L; Schoeffler P; Wessel P; Navé S; Brown RA; Hahne WF
J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
[TBL] [Abstract][Full Text] [Related]
4. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Korttila K; Clergue F; Leeser J; Feiss P; Olthoff D; Payeur-Michel C; Wessel P; Nave S; Hahne W; Brown R
Acta Anaesthesiol Scand; 1997 Aug; 41(7):914-22. PubMed ID: 9265937
[TBL] [Abstract][Full Text] [Related]
5. Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery.
Graczyk SG; McKenzie R; Kallar S; Hickok CB; Melson T; Morrill B; Hahne WF; Brown RA
Anesth Analg; 1997 Feb; 84(2):325-30. PubMed ID: 9024022
[TBL] [Abstract][Full Text] [Related]
6. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
Kovac AL; Scuderi PE; Boerner TF; Chelly JE; Goldberg ME; Hantler CB; Hahne WF; Brown RA
Anesth Analg; 1997 Sep; 85(3):546-52. PubMed ID: 9296407
[TBL] [Abstract][Full Text] [Related]
7. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
Danner K; Becker HG; Best B; Madler C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
[TBL] [Abstract][Full Text] [Related]
9. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
Diemunsch P; Korttila K; Leeser J; Helmers JH; Wilkey B; Navé S; Radke AJ; Hahne WF; Brown RA
J Clin Anesth; 1998 Mar; 10(2):145-52. PubMed ID: 9524901
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
Bey P; Wilkinson PM; Resbeut M; Bourdin S; Le Floch O; Hahne W; Claverie N
Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.
Warriner CB; Knox D; Belo S; Cole C; Finegan BA; Perreault L
Can J Anaesth; 1997 Nov; 44(11):1167-73. PubMed ID: 9398956
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
14. Postoperative nausea and vomiting after surgery for prognathism: not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol.
Piper SN; Röhm K; Boldt J; Kranke P; Maleck W; Seifert R; Suttner S
J Craniomaxillofac Surg; 2008 Apr; 36(3):173-179. PubMed ID: 18353666
[TBL] [Abstract][Full Text] [Related]
15. Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation.
Fauser AA; Russ W; Bischoff M
Support Care Cancer; 1997 May; 5(3):219-22. PubMed ID: 9176968
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group.
Philip BK; McLeskey CH; Chelly JE; McKenzie R; Kovac AL; Diemunsch P; DuBois DM
J Clin Anesth; 2000 Feb; 12(1):1-8. PubMed ID: 10773500
[TBL] [Abstract][Full Text] [Related]
17. Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting.
Korttila KT; Jokinen JD
J Clin Anesth; 2004 Aug; 16(5):364-70. PubMed ID: 15374558
[TBL] [Abstract][Full Text] [Related]
18. The effect of timing of dolasetron administration on its efficacy as a prophylactic antiemetic in the ambulatory setting.
Chen X; Tang J; White PF; Wender RH; Quon R; Sloninsky A; Naruse R; Kariger R; Webb T; Norel E
Anesth Analg; 2001 Oct; 93(4):906-11. PubMed ID: 11574355
[TBL] [Abstract][Full Text] [Related]
19. Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group.
Philip BK; Pearman MH; Kovac AL; Chelly JE; Wetchler BV; McKenzie R; Monk TG; Dershwitz M; Mingus M; Sung YF; Hahne WF; Brown RA
Eur J Anaesthesiol; 2000 Jan; 17(1):23-32. PubMed ID: 10758440
[TBL] [Abstract][Full Text] [Related]
20. Single-dose, placebo-controlled, phase I study of oral dolasetron.
Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
